瘦身神器真的這麼神嗎？瘦瘦筆和猛健樂的副作用是什麼？猛健樂跟瘦瘦筆差在哪？｜Sara的健康大解密 EP.59｜賴宇凡Sara

#瘦瘦筆 #猛健樂 #瘦身 【🌟 我的個人保健品牌｜天天自然】 https://www.gonatural365.com 【 🌱 FB討論社團｜賴宇凡—根治飲食，天天開心 】   / 920092528012080   【 天天自然 官方Line｜客服、最新消息 】 https://lin.ee/IC2825H 🎬 本集影片大綱 0:00｜前言：瘦瘦筆 0:51｜先認識瘦瘦筆幫你瘦身的四大生理功效 2:25｜身體何時會自產GLP-1？ 3:50｜既然身體會產GLP-1，我們為何還會胖？ 5:02｜瘦瘦筆的副作用1 5:36｜瘦瘦筆的副作用2 6:09｜瘦瘦筆的副作用3 6:38｜瘦瘦筆的副作用4 8:03｜選對油脂，也會影響到瘦身效果！ 8:57｜猛健樂跟瘦瘦筆差在哪？ 10:24｜不靠瘦身藥物的天然瘦身方法 🔍 如您有不適與疾病相關問題，歡迎到保健管家提問！ 🌟 加入保健管家：https://lin.ee/WsLmi2Q 機器人會透過問答，給與飲食、生活方式與保健品改善的建議～如使用後仍有疑問，或有其他可能成因反饋，歡迎再次來訊給我們唷！ ———— 關於 "保健管家" ———— 💡使用教學： 註冊保健管家AI： https://user202228.pse.is/4wky8u 註冊問題與解答：https://user202228.pse.is/4xb83u ———— 社群連結區 ———— 1️⃣ 賴宇凡Sara 【 臉書 】  / saralye2021   2️⃣ 個人品牌｜天天自然 【 品牌官網 】 https://www.gonatural365.com 【 Line官方帳號｜客服、最新消息 】 https://lin.ee/IC2825H 【 臉書｜最新消息 】  / gonatural365   📧 產品＆合作洽詢｜support@gonatural365.com ———— HASHTAG ———— #賴宇凡 #GLP1 #減重 #瘦身副作用 #胰臟炎 #膽結石 #倒金字塔飲食 #2025美國膳食指南 #血糖平穩 #胰島素阻抗 #自然醫學 #根治飲食 #脂肪分解 #肝膽排毒 #健康減肥 #猛健樂副作用 #減肥藥真相 #TGR5 #健康大解密 #教學 #醫療新知 #健康 #保健 #運動 #DietaryGuidelines #FoodPyramid #WholeFoods #BloodSugarBalance #InsulinResistance #AdrenalFatigue #HealthyWeightLoss #MetabolicHealth #Wellness2026 #NutritionTruths ———— 參考文獻 ———— Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014). Adverse Effects of GLP-1 Receptor Agonists. The review of diabetic studies : RDS, 11(3-4), 202–230. https://doi.org/10.1900/RDS.2014.11.202 Aimelet, V., & Holst, J. J. (2026). Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes. Diabetes, obesity & metabolism, 28(2), 803–816. Yılmaz, Nimet & Bastemir, Mehmet. (2026). Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations. Diabetes, Metabolic Syndrome and Obesity. 19. 1-13. 10.2147/DMSO.S584175. Drucker D. J. (2024). The GLP-1 journey: from discovery science to therapeutic impact. The Journal of clinical investigation, 134(2), e175634. Alhazmi, A. Roux, C. (2026). Do no harm: Managing nausea and vomiting in GLP-1 based obesity therapies. Frontiers in Endocrinology, 17(1788698). Kasagga, A., Rebellow, D., Hashmi, T., Husami, M. Y., Lama, P., Arul Selvan, K., & Nakasagga, K. (2025). Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials. Cureus, 17(8), e90335. Liu, Z., Yu, S., Jin, X., Sheng, L., YanMu, M. R., Gao, J., Lu, J., & Lei, T. (2025). The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review. Drug design, development and therapy, 19, 10383–10409. Medicines and Healthcare products Regulatory Agency (MHRA). (2026). Drug safety update: GLP-1 and dual GLP-1/GIP receptor agonists—strengthened warnings on acute pancreatitis. GOV.UK. West, S., et al. (2026). Weight regain after cessation of medication for weight management: Systematic review and meta-analysis. The BMJ, 392, e085304.